Replimune Group, Inc.
REPL
Rank in Stocks
#5737
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering... Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Share Price
$22.26
Last synced: 2026-11-09
Market Cap
$2.11B
Change (1 day)
2.96%
Change (1 year)
143.81%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Replimune Group, Inc. (REPL)
Category
Healthcare
Earnings for Replimune Group, Inc. (REPL)
Earnings in Sep 2026 TTM: $-271.59M
According to Replimune Group, Inc.'s latest financial reports, its current earnings (TTM) are $-271.59M. In 2025 the company earned $-246.83M, a decrease compared to its 2024 earnings of $-215.39M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Replimune Group, Inc. from 2017 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-271.59M | 10.03% |
| 2025 | $-246.83M | 14.60% |
| 2024 | $-215.39M | 23.79% |
| 2023 | $-174.00M | 43.55% |
| 2022 | $-121.21M | 44.85% |
| 2021 | $-83.68M | 59.01% |
| 2020 | $-52.63M | 70.67% |
| 2019 | $-30.83M | 56.50% |
| 2018 | $-19.70M | 155.74% |
| 2017 | $-7.70M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -1,852.49% |
US
|
|
| $-2.73B | 904.84% |
US
|
|
| $-4.02B | 1,378.80% |
AU
|
|
| $2.83B | -1,140.49% |
BE
|
|
| $1.50B | -651.19% |
NL
|
Questions about Replimune Group, Inc.'s net income
What is Replimune Group, Inc.'s net income?
Replimune Group, Inc.'s net income over the last twelve months is $-271.59M, as of Sep 2026.
What was Replimune Group, Inc.'s net income in 2025?
In 2025, Replimune Group, Inc.'s net income was $-246.83M, compared with $-215.39M in 2024.
How has Replimune Group, Inc.'s net income changed since 2020?
From 2020 to 2025, Replimune Group, Inc.'s net income was highest in 2020 ($-52.63M) and lowest in 2025 ($-246.83M).
How does Replimune Group, Inc.'s net income compare with similar companies?
Replimune Group, Inc.'s net income ($-271.59M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.